Abstract: The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate.
Type:
Application
Filed:
April 24, 2015
Publication date:
March 17, 2016
Applicant:
CymaBay Therapeutics, Inc.
Inventors:
Diego Broggini, Hartmut Burghard Zinser
Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
May 4, 2015
Publication date:
February 25, 2016
Applicant:
CymaBay Therapeutics, Inc.
Inventors:
Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
Type:
Grant
Filed:
June 21, 2011
Date of Patent:
January 26, 2016
Assignee:
CYMABAY THERAPEUTICS, INC.
Inventors:
Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
Type:
Grant
Filed:
February 25, 2015
Date of Patent:
January 12, 2016
Assignees:
CYMABAY THERAPEUTICS, INC., DIATEX, INC.
Inventors:
Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
Abstract: Treatment of severe hypertriglyceridemia, such as Type I or Type V hyperlipoproteinemia, by therapy with MBX-8025 or an MBX-8025 salt, alone or in combination with one or more of a fibrate, niacin, and an omega-3 fatty acid, optionally accompanied by apheresis.
Type:
Application
Filed:
June 25, 2015
Publication date:
December 31, 2015
Applicant:
CymaBay Therapeutics, Inc
Inventors:
Pol Boudes, Yun-Jung Choi, Robert L. Martin, Charles A. McWherter
Abstract: Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.
Type:
Grant
Filed:
August 25, 2014
Date of Patent:
October 6, 2015
Assignee:
Cymabay Therapeutics, Inc.
Inventors:
Jiangao Song, Charles A. McWherter, Fang Ma, Mark Andres, Igor Ivanisevic, Ekaterina Albert, Patricia Andres
Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
March 24, 2015
Publication date:
September 17, 2015
Applicant:
CymaBay Therapeutics, Inc.
Inventors:
Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.
Type:
Application
Filed:
February 19, 2015
Publication date:
August 27, 2015
Applicant:
CymaBay Therapeutics, Inc.
Inventors:
Xin Chen, Peng Cheng, L. Edward Clemens, Jeffrey D. Johnson, Jingyuan Ma, Alison Murphy, Imad Nashashibi, Christopher J. Rabbat, Jiangao Song, Maria E. Wilson, Yan Zhu, Zuchun Zhao
Abstract: Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.
Type:
Application
Filed:
August 25, 2014
Publication date:
July 16, 2015
Applicant:
CYMABAY THERAPEUTICS, INC.
Inventors:
Jiangao Song, Charles A. McWherter, Fang Ma, Mark Andres, Igor Ivanisevic, Ekaterina Albert, Patricia Andres
Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
June 23, 2015
Assignee:
CYMABAY THERAPEUTICS, INC.
Inventors:
Brian Edward Lavan, Gopal Chandra Saha, Charles A. McWherter, Brian K. Roberts
Abstract: Treatment of homozygous familial hypercholesterolemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an MTP inhibitor, an apoB-100 synthesis inhibitor, or a PCSK9 inhibitor.
Type:
Application
Filed:
November 14, 2014
Publication date:
May 21, 2015
Applicant:
CymaBay Therapeutics, Inc.
Inventors:
Robert L. Martin, Charles A. McWherter, Patrick J. O'Mara
Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
May 5, 2015
Assignee:
Cymabay Therapeutics, Inc.
Inventors:
Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
Type:
Grant
Filed:
July 10, 2013
Date of Patent:
March 31, 2015
Assignee:
Cymabay Therapeutics, Inc.
Inventors:
Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.
Type:
Grant
Filed:
September 12, 2012
Date of Patent:
March 10, 2015
Assignee:
Cymabay Therapeutics, Inc.
Inventors:
Xin Chen, Peng Cheng, L. Edward Clemens, Jeffrey D. Johnson, Jingyuan Ma, Alison Murphy, Imad Nashashibi, Christopher J. Rabbat, Jiangao Song, Maria E. Wilson, Yan Zhu, Zuchun Zhao
Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.
Type:
Grant
Filed:
January 16, 2013
Date of Patent:
December 30, 2014
Assignee:
CymaBay Therapeutics, Inc.
Inventors:
Xin Chen, Peng Cheng, L. Edward Clemens, Jeffrey D. Johnson, Jingyuan Ma, Alison Murphy, Imad Nashashibi, Christopher J. Rabbat, Jiangao Song, Maria E. Wilson, Yan Zhu, Zuchun Zhao
Abstract: The present application discloses a process for the preparation of a halofenate compound of the formula (III) or a salt thereof: wherein R, X and X? are as defined herein, the process comprising contacting a compound of formula (Ia) with a compound of formula (Ib) and N,N?-dicyclohexylcarbodiimide under conditions sufficient to form the compound of formula (III).
Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.
Type:
Grant
Filed:
May 3, 2012
Date of Patent:
September 30, 2014
Assignee:
Cymabay Therapeutics, Inc.
Inventors:
Jingyuan Ma, Christopher J. Rabbat, Jiangao Song, Xin Chen, Imad Nashashibi, Zuchun Zhao, Aaron Novack, Dong Fang Shi, Peng Cheng, Yan Zhu, Alison Murphy
Abstract: Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.
Type:
Grant
Filed:
March 28, 2013
Date of Patent:
August 26, 2014
Assignee:
Cymabay Therapeutics, Inc.
Inventors:
Jiangao Song, Charles A. McWherter, Fang Ma, Mark Andres, Igor Ivanisevic, Ekaterina Albert, Patricia Andres